Navigation Links
Researchers discover why steroid treatment for COPD is ineffective
Date:10/18/2011

Chronic obstructive pulmonary disease (COPD) leads to persistent inflammation of the airways and is typically managed with corticosteroids, a class of anti-inflammatory medication. However, corticosteroids do not improve survival nor alter the progression of COPD and may reduce lung symptoms as little as 20 percent. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health, found why corticosteroids do not work well for COPD patients and how additional treatment with sulforaphanean ingredient of broccoli and other vegetablescan improve the effectiveness of corticosteroids. The study was published online October 17, 2011, in advance of print in the Journal of Clinical Investigation.

COPD is a major public health problem for both the developed and the developing world, and is most often caused by cigarette smoking or exposure to pollutants from combustion. Characterized by chronic bronchitis and emphysema, COPD is the third leading cause of death in the U.S. and affects 24 million Americans and 210 million people worldwide.

Histone deacetylase 2 (HDAC2) is critical component in a chain of reactions that enable corticosteroids to reduce inflammation. However, HDAC2 is substantially reduced in the lung tissue of individuals with COPD. In the study, Johns Hopkins researchers found that S-nitrosylation causes HDAC2 dysfunction and leads to corticosteroid insensitivity in the alveolar macrophages of the lungs of individuals with COPD. S-nitrosylation of HDAC2 occurs from exposure to cigarette smoke, a primary cause of COPD.

"This study provides the mechanism of exaggerated inflammation observed in COPD patients during exacerbations, which has been a barrier to developing effective therapy," said Rajesh Thimmulappa, PhD co-author of the study and an assistant scientist in the Bloomberg School's Department of Environmental Health Sciences.

Furthermore, the research team found that treatment with sulforaphane restored HDAC2 activity and corticosteroid sensitivity. Previous studies by the research team showed sulforaphane activates the Nrf2 pathway (nuclear factor erythroid 2related factor 2) and it is being tested in clinical trial for patients with COPD.

"Restoring corticosteroid sensitivity in patients with COPD by targeting the Nrf2 pathway holds promise for effectively treating exacerbations," said Shyam Biswal, PhD, senior author of the study and professor in the Bloomberg School's Department of Environmental Health Sciences and Division of Pulmonary and Critical Care Medicine at the Johns Hopkins School of Medicine.


'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 2017 , ... American Veterinarian™, the leading multimedia provider and ... the launch of Veterinarian’s Money Digest™, a business and financial resource for veterinary ... Veterinarian™. , “We look forward to launching Veterinarian’s Money Digest™,” said ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... The comprehensive weight management program at Women’s Excellence will help patients lose weight ... and physical exam. The specialists at Women's Excellence will measure BMI, body ...
(Date:3/27/2017)... NY (PRWEB) , ... March 27, 2017 , ... ... in epigenetic research products enables researchers to pursue the recent RNA methylation “gold ... methylation . In light of the newfound characteristics of N6-methyladenosine, or m6A ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare and ... hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide ... and value analysis professionals have a ‘seat at the table’ with clinical committees ...
(Date:3/27/2017)... Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... men with prostate cancer, including all stages, is more than 95%. Once the cancer ... drastically to less than 30%. To find out how to avoid this latter group, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... and is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of ... generate the highest revenue, and is projected to dominate the market during the study ... ... Allied Market Research Logo ...
(Date:3/24/2017)... , March 24, 2017  Zymo ... company, and Hamilton Robotics, Inc., who designs, ... an ongoing collaboration that teams Zymo Research,s ... RNA and DNA extraction products with Hamilton,s ... created optimized methods for microbiomics and RNA ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... their offering. ... analyzes the worldwide markets for Dental Implants in US$ Million. The report ... Japan , Europe , ... World. Annual estimates and forecasts are provided for the ...
Breaking Medicine Technology: